APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 262 filers reported holding APELLIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,598,441 | -61.5% | 42,020 | -7.7% | 0.00% | -66.7% |
| Q2 2023 | $4,149,601 | +2.2% | 45,550 | -26.0% | 0.00% | -25.0% |
| Q1 2023 | $4,058,383 | +443.6% | 61,528 | +326.2% | 0.00% | +300.0% |
| Q4 2022 | $746,537 | -22.1% | 14,437 | +2.9% | 0.00% | 0.0% |
| Q3 2022 | $958,000 | +163.2% | 14,032 | +74.3% | 0.00% | – |
| Q2 2022 | $364,000 | +12.3% | 8,049 | +26.1% | 0.00% | – |
| Q1 2022 | $324,000 | +0.3% | 6,385 | -6.7% | 0.00% | – |
| Q4 2021 | $323,000 | +35.1% | 6,840 | -5.7% | 0.00% | – |
| Q3 2021 | $239,000 | -49.7% | 7,256 | -3.5% | 0.00% | – |
| Q2 2021 | $475,000 | -28.7% | 7,520 | -51.5% | 0.00% | -100.0% |
| Q1 2021 | $666,000 | +88.7% | 15,518 | +151.2% | 0.00% | – |
| Q4 2020 | $353,000 | +68.1% | 6,178 | -3.8% | 0.00% | – |
| Q2 2020 | $210,000 | -4.1% | 6,422 | -21.4% | 0.00% | – |
| Q1 2020 | $219,000 | – | 8,175 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Octagon Capital Advisors LP | 3,130,000 | $119,065,200 | 18.29% |
| EcoR1 Capital, LLC | 10,899,859 | $414,630,636 | 13.99% |
| Ally Bridge Group (NY) LLC | 181,805 | $6,915,862 | 8.12% |
| Avoro Capital Advisors LLC | 11,111,111 | $422,666,662 | 6.59% |
| ACUTA CAPITAL PARTNERS, LLC | 244,484 | $9,300,171 | 6.23% |
| Iron Triangle Partners LP | 880,000 | $33,475,200 | 4.89% |
| Cormorant Asset Management, LP | 2,000,000 | $76,080,000 | 4.44% |
| Octagon Capital Advisors LP | 675,000 | $25,677,000 | 3.94% |
| Logos Global Management LP | 750,000 | $28,530,000 | 3.81% |
| Boxer Capital, LLC | 1,726,000 | $65,657,040 | 3.50% |